In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer’s Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered with Silo to study psychedelics’ ability to improve, slow, or even reverse functional decline and memory loss associated with Alzheimer’s disease. Associate Professor of Clinical Neurobiology, Dr. Christine Ann Denny, helming the research for Silo, explores “the molecular mechanisms underlying learning and memory,” and has co-authored research detailing psychedelic treatment for depression, mechanisms of age-related memory loss, mood improvement and stress reduction. Silo Parma CEO Eric Weisblum expressed encouragement on partnering with Dr. Denny and Columbia University. “To be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer’s disease is an exciting proposition for Silo Pharma.” The Mayo Clinic defines Alzheimer’s Disease as an incurable and progressive “neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. [AD] is the most common cause of dementia — a continuous decline in thinking, behavioral and social skills that affects a person’s ability to function independently.” The National Institute on Aging (“NIA”), one of the 27 institutes and centers forming The National Institutes of Health (“NIH”), offers the following AD facts:

• Over 6 million Americans, mostly over 65, may have AD-related dementia.
• AD ranks seventh among all leading causes of US deaths and is the most “common cause of dementia among older adults.”
• Early-onset AD affects people between their 30s and mid-60s though represents under 10% of Alzheimer’s patients.
• Behavioral symptoms include sleeplessness, wandering, agitation, anxiety, and aggression.
• Diagnosis includes performing standard medical tests and various brain scans, ascertaining medical history, personality or behavioral changes, current mental health issues and cognitive, memory and self-care abilities.
• AD is degenerative and worsens at different rates among patients, from early mild AD symptoms to complete dependence on caretakers.
• Alzheimer’s Disease International states that the “annual global cost of dementia is now above US$ 1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030.”

Currently, there is no AD cure.  Studies have pointed towards preventative methods, according to the AAFP, “that may affect the incidence of [AD], such as the use of dietary supplements and pharmacologic agents” as well as lifestyle choices and circumstances, including “diet, socioeconomic factors, medical conditions, and environmental exposures,” though these studies have been unable to prove actual causation or efficacy. Drugs used to treat mild to severe AD symptoms include “galantamine, rivastigmine, and donepezil … cholinesterase inhibitors that … may help reduce or control some cognitive and behavioral symptoms.”  Science can’t explain why these drugs work and all lose efficacy over time as AD progresses. Side effects include “nausea, vomiting, diarrhea, decreased appetite, dizziness, headache.” Aducanumab, the only FDA-approved disease-modifying drug for AD treatment, targets “brain lesions associated with Alzheimer’s,” though effectiveness has only been studied on those with early or mild symptoms.  Aducanumab is “administered intravenously (“IV”) via a 45- to 60-minute infusion every 4 weeks” and may “slow the progression of the earliest symptoms…” Side effects can be serious, including “brain inflammation called amyloid-related imaging abnormalities (‘ARIA’), which involves brain bleeding, brain swelling, or a combination of the two.” A peer-reviewed article in Frontiers in Synaptic Neuroscience illustrates the interest in psychedelics by the AD medical community,  particularly “their potential to stimulate neurogenesis [process of generating functional neurons], provoke neuroplastic changes [structural and functional changes to the brain] and reduce neuroinflammation. This inevitably makes them interesting candidates for therapeutics in dementia.” Some important points raised in the article:

• Psychedelics induce brain plasticity and modify connectivity between brain regions and there is considerable anecdotal evidence of cognitive benefits from micro-dosing—a dose that does not cause perceptual change or impair functioning…
• A 2018 uncontrolled, open-label naturalistic trial found increased cognitive fluency, flexibility, and originality amongst the 33 participants at various micro-doses of psilocybin… In general, the medication was well tolerated with no serious adverse events or drop-outs.
• In treatment-resistant depression, 10 mg and 25 mg of psilocybin given 1 week apart  … led to clinical response or remission in 14 participants sustained at assessment 5 weeks later. This effect persisted at 6 months follow up despite no further treatment…
• In AD there is a reduction in global brain glucose metabolism … In the only psilocybin FDG-PET study to date … ingestion of a 15 mg or 20 mg dose increased global brain glucose metabolism by approximately 25% …
• All known genetic and environmental risk factors for AD are associated with increased inflammation … Psychedelics have been shown to have potent anti-inflammatory properties and … may represent a unique anti-inflammatory overwhelmingly targeted to brain tissue …

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science, in the Journal of Psychopharmacology states that “The first RCT [randomized controlled trial] comparing psilocybin to a conventional selective serotonin reuptake inhibitor (‘SSRI’) antidepressant found the former to be as efficient at reducing symptoms of depression, and with fewer side effects … Most researchers now consider classic psychedelics to be non-toxic, that is, they do not damage mammalian organ systems, and as physiologically safe, even in very high doses…” Alongside Silo’s work with Columbia University, they’re also exploring methods for delivering psychedelic therapeutics in extremely targeted doses.  Partnering with the University of Maryland Baltimore, Silo believes central nervous system (“CNS”) homing peptides can deliver a microdose “payload” to inflamed tissue while bypassing healthy organs. A Silo Pharma news release says, “the ability to deliver psilocybin and other psychedelic compounds directly to targeted areas of the body … could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed.” Silo’s partnership developing Zylo Therapeutics Z-pod technology for sustained transdermal delivery delivers time-released ketamine or psilocybin which will, says Silo CEO Eric Weisblum, “allow [Silo] to explore both the safety and efficacy of our therapeutics while hopefully diminishing the hallucinogenic effects of psychedelics.  We believe that Zylo’s patented technology will allow us to reach potential patients suffering from dysphagia, an inability to swallow affecting those with severe AD. Silo is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease. We eagerly await results from recent research which utilizes cutting-edge psychedelic therapeutics and traditional treatments.” For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• The global indoor farming market projected to grow from $26.5 billion in 2021 to $62 billion by 2030
• Report indicates that United States holds major share in terms of revenue in North America indoor farming market
• Grow Pods offered through ACTX provide a controlled environment, ability to grow year-round

The newest projections for the global indoor farming sector are in, and the numbers bode well for Advanced Container Technologies (OTC: ACTX). ACTX is the exclusive U.S. distributor of Grow Pods, environmentally controlled micro-farms that allow cultivation of ultra-clean crops all year long. “The study undertaken by Astute Analytica foresees a tremendous growth in revenue of the market for the global indoor farming market from US$26.5 billion in 2021 to US$62 billion by 2030,” a recent PR Newswire report states (https://ibn.fm/DUwJn). “The market is anticipated to grow at a CAGR of 10.1% during the forecast period 2022–2030. The article notes that indoor vertical farming is defined as the practice of growing produce stacked one above another in a closed, controlled environment. “Growing crops on vertically mounted shelves significantly reduces the amount of land space needed to grow plants compared to traditional farming methods,” the article observes. “Vertical farms are unique in the sense that some setups do not require soil for plants to grow,” the article continues. “Most are either hydroponic, where vegetables are grown in a nutrient-dense bowl of water, or aeroponic, where the plant roots are systematically sprayed with water and nutrients. Moreover, vertical farms use smart sensors to monitor technical variables including temperature, carbon dioxide, oxygen, lighting, humidity, nutrient concentration, pH, pest control, irrigation and harvesting.” The Astute Analytica report showed that the United States holds the major share in terms of revenue in the North America indoor farming market, with projections to grow with the highest CAGR during the forecast period. “Moreover, developed countries such as U.S. and Canada are the rapid and early adopters of indoor farming technologies,” the article said. “Furthermore, based on the growing system, the hydroponics segment holds the highest share in the North America indoor farming market in 2021 as it reduces the amount of space and water required for cultivation.” Offering the ability to grow high-quality crops anywhere, the Grow Pods offered through Advanced Container Technologies provide a controlled environment and the ability to grow year-round. The micro-farms also enable cultivation in a smaller footprint using less resources — huge advantages in a world where environmental and sustainability concerns are top priorities for consumers. In November 2020, ACTX announced that it had entered into an agreement with Grow Pods manufacturer GP Solutions for the exclusive right to market, sell and distribute GP products in the United States and its territories (https://ibn.fm/AP3PQ). At the time of the agreement, GP Solutions president George Natzic stated that “we are very enthusiastic about this agreement and look forward to letting the experts at ACT handle sales and marketing while we focus on manufacturing new products, and expanding into new industries and territories.” For more information, visit the company’s website at www.AdvancedContainerTechnologies.com. NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://ibn.fm/ACTX

• Cepton develops lidar sensors for ADAS and autonomous driving, and has been awarded the largest lidar production contract to date with products set to debut next year across General Motor’s Ultra Cruise ADAS platform
• Award covers 4 target vehicle models in 2023, 4+ models in 2024, and an anticipated 4+ models in 2025 with Cadillac being the first to introduce the Ultra Cruise technology
• Cepton’s proprietary MMT(R) technology provides a highly competitive price for performance and reliability
• Founder-led, visionary management team with substantial “skin in the game”

Since becoming public in early 2022, Cepton (NASDAQ: CPTN) has not deviated from its plan to be a leader in lidar. The Silicon Valley-based company made D-sample shipments in Q1 in support of GM’s Ultra Cruise program, which is the final stage before scale production, and is on-track to potentially be the world’s first lidar company to have its products found in consumer vehicles. Lidar, an acronym for light detection and ranging, is a remote sensing technology that bounces light off surrounding objects to accurately create a map of the environment. Lidar has been around for decades and has emerged as an integral component in advanced driver assistance systems (“ADAS”) and autonomous vehicles. In addition, lidar can be used in various non-automotive applications, enabling smart cities, automated tolling, last-mile delivery, autonomous trucking, robotics, etc. High cost has been one major problem with lidar systems for automakers, reserving it to only high-end models. Cepton has helped address this issue with its MMT(R) (micro-motion technology) lidar system, which was developed with mass market consumer vehicles in mind and has attracted the attention of top automotive OEMs (original equipment manufacturers) and Koito Manufacturing, a leading tier-1 automotive lighting supplier that has invested $100 million in Cepton. Cepton along with its tier-1 partner Koito Manufacturing is the recipient of the largest known ADAS lidar series production award to date with its lidar systems integrated into GM’s Ultra Cruise program. This program is expected to be released in 2023 on select GM vehicles with Cadillac being the first to introduce the technology. The Ultra Cruise advanced driver assist system is designed to enable door-to-door hands-free driving in 95 percent of all driving scenarios in North America. GM has agreed to use Cepton lidar products for its first 9 models that will offer Ultra Cruise in 2023 and 2024 and the companies are collaborating on potential additional models that will be introduced in 2025 and beyond. Cepton is currently engaged with all top 10 automotive OEMs worldwide. Cepton is advancing multiple projects worldwide in smart infrastructure. For example, Cepton partnered with The Indoor Lab to provide real-time crowd analytics at Orlando International Airport, which helped create one of the world’s safest terminals during the COVID-19 pandemic, covering roughly 50K square feet of terminal area. Cepton has recently worked with Fibre Based Integrations, an established fiber optics system house in South Africa to develop a lidar-based vehicle detection system in Cape Town to monitor lane usage. Cepton continues to invest in developing its portfolio of next generation products and technologies including its near range lidar, Nova, which were shipped to multiple global top-10 automotive OEMs (B-samples) for evaluation this quarter. The company also recently completed the architecture design for its second ASIC with tape out expected by the end of the year. This ASIC is a scalable companion chip to Cepton’s first ASIC with an emphasis on electronics component integration that reduces cost and dependency on the electronics supply chain. Cepton announced this month the opening of its new corporate office in Metro Detroit (Troy, MI) to serve as its automotive hub as the company continues to expand its active engagements and initiatives with OEMs. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Golden Matrix Group recently reported its 15th consecutive quarter of profitability
• GMGI’s second quarter revenues rose 221% YoY with net income expanding by upwards of 359% YoY
• GMGI attributed the rise in revenues to the added contribution from UK-based competition company, RKingsCompetitions Ltd, which Golden Matrix acquired in November 2021
• Management expressed their continued optimism on GMGI’s future prospects, with the company’s B2B and B2C verticals both showing robust growth

Fifteen consecutive quarters of profitability is a remarkable feat; even Amazon, the world’s largest e-commerce operator, reported a net loss over the past three months. Moreover, Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, achieved the feat in impressive fashion. The company recently reported financial results for its second fiscal quarter, with quarterly revenues rising by 221% year-over-year to $8,482,743. Meanwhile, Q2 net income rose to $586,984, a significantly increase relative to the $127,986 recorded in the equivalent period a year ago (https://ibn.fm/fBB9z). Golden Matrix Group attributed part of the significant increase in year-over-year revenues to the 28% increase in GMGI’s B2B segment’s top-line, in addition to strong revenue contributions from RKings. Golden Matrix Group acquired an 80 percent controlling stake in UK-based RKingsCompetitions Ltd in November 2021, with the company contributing 60 percent of GMGI’s total revenues in the quarter. Notably, GMGI also recorded a significant boost to their net income margin, with the latter figure expanding from 4.85 percent in Q2 last fiscal year to 6.92 percent in the most recent quarter. Perhaps more impressively, the company’s net margin widened despite a significant rise in GMGI’s cost base, with general and administrative expenses rising 321 percent year-over-year to $1,380,706 in the most recent quarter. The increase in costs was primarily due to G&A expenses arising from the RKings acquisition, which included payroll costs as well as bank charges for transaction fees. “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “During the quarter we implemented upgraded technology and stronger accounting controls to improve cash flow and profitability at RKings. With the Tournament Platform’s added features and functionality, we expect steady increases in both the monthly number of skill tournaments and participants; and, because this robust platform gives RKings’ tournament players immediate access to a growing number of exciting prize competitions, we expect this third quarter and future quarters to generate increasing revenues and profits. GMGI has recently targeted its efforts on growing out both, their B2B and B2C verticals in recent months. On the B2B side, the company recently announced the launch of their revamped GM-X turnkey solution, a complete software package designed to support online gaming businesses. Benefitting from their partnership with upwards of 25 providers, GMGI have established a robust portfolio of over 10,000 games ranging from online slots, casino table games, live operator games, and more, which are then licensed to gaming platform operators seeking to operate a proven set-up. Golden Matrix Group have also simultaneously sought to grow out their B2C segment, most recently through the acquisition of RKingsCompetitions Ltd. In addition to contributing approximately $5.1 million of the group’s total revenues for the quarter, RKings’s unique competitions have also resulted in GMGI acquiring over forty five thousand new players a quarter at relatively low cost – a crucial factor towards growing out their addressable consumer universe going forward. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs
• The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria’s own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands
• The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
• Lexaria also recently announced an agreement with Ireland’s Anodgen Bioceuticals that allows Anodgen to manufacture and distribute DehydraTECH processed cannabinoid API powders within Europe including the UK, Australia and New Zealand

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has built the reputation of its patented DehydraTECH drug delivery technology through a growing data set of potential medicinal applications and through an expanding list of licensing agreements with third-party companies interested in its potential for cannabidiol (“CBD”)-based products. Lexaria’s patented DehydraTECH technology transforms a wide variety of orally and topically administered products into enhanced solutions that make the APIs more rapidly available and effective at lower doses while adding zero chemical byproducts. Among the licensing partnerships announced by the company are recent agreements with beverage developer BevNology and Ireland API manufacturer and distributor Anodgen Bioceuticals. The BevNology collaboration was announced June 21 and not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand, but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta. “These agreements build on a long standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” Lexaria CEO Chris Bunka stated in announcing the BevNology development (https://ibn.fm/wb0e3). “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.” The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands.  Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility. The licensing agreement addresses powdered DehydraTECH formulations and liquid formulations that tend toward BevNology’s particular expertise. Both elements of the agreement are non-exclusive, except that the liquid formulations have limited exclusivity in the United States and complete exclusion in Japan, the Republic of Korea, and the People’s Republic of China. The Anodgen licensing agreement was announced earlier in the month and includes a five-year non-exclusive DehydraTECH license for powdered CBD-based products in Europe including the United Kingdom, Australia, and New Zealand. Under the license, Anodgen can use DehydraTECH not only for making and selling medical application CBD products but also pharmaceutical applications for psychoactive cannabinoids (https://ibn.fm/aXPCD). Anodgen is building a new facility in Ireland and expects to be fully operational later this year, creating the potential for long-term use of DehydraTECH for the pharmaceutical market. Independent third-party testing has evidenced DehydraTECH’s ability to enhance the performance of a variety of pharmaceutical and wellness industry products and has led to a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file DehydraTECH-CBD as a prospective registered treatment for hypertension this year (https://ibn.fm/w5xaX). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage
• The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device
• Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion
• In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate

Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions that offer clinical advantages to unmet medical needs. The company boasts a repertoire of several products that include the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device, both of which are in development and are, therefore, not yet commercially available, as well as a novel breath-propelled nasal delivery device designed to deliver the company’s novel treatment for concussion, PRV-002. Nasal Delivery Device The nasal delivery device, which was the subject of a patent application filed last fall (https://ibn.fm/9c2KZ), is part of a drug-device combination that is being used in Odyssey’s ongoing Phase I clinical trial investigating how well PRV-002 is tolerated by healthy human subjects. “It’s a small device that essentially delivers a powdered drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within 5 minutes and spreads out throughout the brain within 30 minutes, reversing the effects of a concussion,” explained Odyssey CEO Michael Redmond in a recent interview with RedChip Companies CEO Dave Gentry (https://ibn.fm/Pz8SE). The device provides Odyssey with the opportunity to get PRV-002 into the brain rapidly after a concussion, a factor that, coupled with the drug’s safety profile and lack of adverse side effects as indicated by extensive animal trials and initial results from a section of the participants in the Phase I clinical trial, will be instrumental to the company’s success in its clinical trials. PRV-002 Novel Drug Candidate Developed by two neuroscientists, one of whom has a background as a toxicologist, PRV-002 is a compound that Redmond described as a drug cocktail containing three new, proprietary elements that have three mechanisms of action. “Between the two of them, having both toxicology and neurological backgrounds, they created an extremely safe drug compound. We did animal studies that show even at 200 times what we believe to be the dosing, there’s still no toxicity. So, it’s an extremely safe drug, and the efficacy in the animal models is very strong. We have confidence that this will translate into humans,” Redmond continued. The PRV-002 drug is designed to be administered as close to a concussion event as possible, with quicker administration leading to better results. Odyssey has established that there is a window of at least six hours within which the drug shows greater efficacy, if administered. To boost the chances of greater efficacy from quick administration, the PRV-002 drug candidate is available as a dry powder with a long shelf life and does not require special handling or refrigeration. For this reason, it can sit on the sidelines of any football game or sporting event. In addition, soldiers, who are at great risk of suffering blunt trauma from explosives’ shockwaves, bullet penetration, and violent impact, can store it in their backpacks, while emergency response teams can keep it in their ambulances or emergency rooms (“ERs”). When asked how quickly the company expects to begin Phase II clinical trials given the ongoing Phase I clinical trial, Redmond noted, “When we have the Phase I data, we can actually start a Phase II trial in Australia immediately. We have a site set to start a Phase II trial in Australia, likely in the October timeframe. We want to do some of the Phase II or most of it in the U.S., and that requires FDA approval. We have reached out to the FDA to set up that meeting, and hopefully, we’ll have a meeting with the FDA where we can provide our Phase I data in the summer timeframe.” The company is in discussions with the military in the U.S. to undertake the Phase II study at some of the military sites that experience a large number of concussions and has, in fact, formed a Military Advisory Board to help it achieve this goal (https://ibn.fm/j4LAw). Odyssey expects to “be in the U.S. Phase II [clinical trial stage] this year, probably in the fourth quarter,” subject to FDA approval. Strategic Approach Odyssey has strategically planned its Phase II trial to ensure it collects data as soon as the study commences. According to Redmond, the ability to gather data is a function of the number of concussed patients, meaning the company has to set trials at sites that report a high number of concussions. For example, the military has at least two sites that experience over 100 concussions a month. And by setting up the trials at these sites, the company expects to start collecting data immediately upon the start of the trial. Redmond also highlighted the subsequent phases of its drug development journey, noting that the drug could be available for commercialization to Special Populations – a group of people, in this case, the military, that experiences concurrent disease states (https://ibn.fm/O9jh7) – immediately after a successful Phase II trial. That’s because there is currently no FDA-approved treatment for concussion. To facilitate this milestone, Odyssey would be open to partnerships for commercialization, marketing, and distribution. For more information, visit the company’s website at https://odysseygi.com/. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• New meal plan offering includes three meals a day (breakfast, lunch and dinner) up to five days per week
• Model Meals brand is optimal for providing seamless customer experience, substantially increased customer lifetime value
• Move provides opportunity to explore subscription model with other HBIS components, says CEO

Home Bistro (OTC: HBIS), a leading online meal-delivery platform that offers exclusive celebrity chef-inspired, gourmet and lifestyle ready-made meals, is strengthening its commitment to offer exclusive celebrity-chef-inspired, ready-made meals by launching its first subscription-based offering for its Model Meals brand (https://ibn.fm/9wDv9). The new plan offering includes three meals a day (breakfast, lunch and dinner) up to five days per week. “We are excited to finally execute on a long-term strategic objective by establishing a subscription-based meal platform,” said Zalmi Duchman, Home Bistro CEO. “We believe the Model Meals lifestyle brand is optimal for establishing a sticky, recurring revenue model, which provides for a seamless customer experience and a substantially increased customer lifetime value. This also gives us an opportunity to explore the subscription model with other components of our business.” Initially HBIS will offer the subscription-based plans in its southern California market, with plans to expand moving forward. Home Bistro acquired Model Meals in July 2021 in a strategic move to extend its food-production and fulfillment capabilities to the western region of the United States (https://ibn.fm/0JwbH). “This acquisition provides Home Bistro with major benefits on multiple levels,” said Home Bistro CEO Zalmi Duchman. “First, given our now bicoastal operations, we have the ability to ship overnight to most customers within the 48 contiguous states. Next, we acquired a lifestyle brand that has the potential for recurring revenue, subscription-based enrollment and potential for growth to the other 47 states from the current three. Lastly, we add tremendous talent to the Home Bistro management team with Camille, Danika and the senior staff at Model Meals.” Home Bistro’s Model Meals lifestyle brand is a Whole30- and Paleo-approved, ready-to-eat, meal-prep service (https://ibn.fm/RVPRO). The platform offers a weekly menu that rotates. Meal plans are prepared by professional chefs, using only the highest-quality ingredients available, which are sourced responsibly and locally, and delivered in sustainable, ecofriendly packaging. The strategic movement by HBIS comes as a Mordor Intelligence study reports that the “the global ketogenic diet food market is projected to register a CAGR of 5.52% during the forecast period, 2022—2027” (https://ibn.fm/cwJMh). The report notes that the global pandemic and the fact that “online health training websites and various social media platforms have been promoting to intake of healthy diets . . . has increased the consumption of keto-based food and beverage at a faster growth.” For more information, visit the company’s website at www.HomeBistro.com. NOTE TO INVESTORS: The latest news and updates relating to HBIS are available in the company’s newsroom at https://ibn.fm/HBIS

• Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance
• Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics
• Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO

New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The company’s feasibility study using Kernel Flow confirms the device’s ability to successfully measure the neuro-effect of ketamine (https://ibn.fm/blLwT), based on study results presented at the PSYCH Symposium in London. Cybin has announced that preliminary data from the study indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research. “Previously, studies had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. “Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” Drysdale continued. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.” Cybin is partnering with Kernel, a leader in noninvasive neuroimaging, for the study. During the study, participants receive either a low dose of ketamine or a placebo while wearing the Flow headset, which measures cortical hemodynamics experienced during an altered state of consciousness. Data was collected to create a baseline at days 1 through 5, with a dosing administered at day 6, then follow-up data was collected on days 7 through 11, confirming that ketamine-induced changes in functional connectivity lasted for several days after participants received the substance. “Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Bryan Johnson, Founder and Chief Executive Officer of Kernel. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help advance these powerful new therapies for patients.” The feasibility study involves participants wearing Kernel Flow, which features hi-tech sensors to record brain activity, while in an altered state of consciousness following the administration of ketamine. The system records brain activity throughout the four-week study, which is combined with information gathered from questionnaires and validated assessments. Information from the study may be used by Cybin as it develops its two active drug programs, CYB003 and CYB004, which target anxiety and depression (https://ibn.fm/nULws), (https://ibn.fm/gQjHz). CYB003 is a deuterated psilocybin analog derived from psilocybin that is designed to achieve less variability in plasma levels, a faster onset of action and shorter duration of effect, as well as potentially better tolerability, for an overall better outcome for patients. CYB004 is a deuterated dimethyltryptamine (“DMT”) that, in its natural form, is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies show the potential for overcoming these limitations such that deuterated DMT could provide increased oral and pulmonary bioavailability and faster onset, with lower doses, less patient variability, and better dose titration, resulting in fewer side effects and longer-acting desensitization of the serotonergic receptors. CYB004 is also being evaluated for its potential to effectively treat anxiety disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

Sustain Southern California (“Sustain SoCal”) accelerates cleantech economic growth and sustainability initiatives through innovation, collaboration, and education. Sustain SoCal is hosting Driving Mobility – the 9th Annual Transportation Conference. This year’s event will feature succinct presentations by leading c-suite executives, senior management, and industry experts from public sector organizations. Invited speakers will share their perspectives on a multitude of issues, including electrification, V2X, hydrogen/fuel cell, OEM and investor trends, connected vehicles, mobility as a service, incentives, policy, legislation, and sustainability. Mobility and transportation experts, representatives of local and state authorities, potential investors from private equity and venture capital, experts from the battery storage subsector, university faculty, and senior executives from marquee companies such as Virgin Galactic and Volvo N.A., that specialize in mobility and transportation will be in attendance. Key aspects of this event:

• Driving Mobility 9 is a one-day in-person event. The conference will be from 1:00-5:00 pm and the EXPO and reception will be held from 5:00-7:30 pm
• The event will take place at UCI Beall Applied Innovation
• The event is free of cost for Sustain SoCal Members.
• Presentations will be brief, packed with information, insights, and to the point.
• The event will also host an Innovators Showcase, where c-suite executives will present their latest research and development to attendees.
• An in-person EXPO and reception will be held to conclude the event.

Who’s Organizing This Event? Sustain SoCal is a non-profit organization based at UCI Beall Applied Innovation, that proactively addresses Southern California’s sustainability, environmental and infrastructure needs and objectives. The organization gathers stakeholders via industry-leading conferences, workshops, and networking events to positively impact the region’s economic progress and sustainable future. During its long history, Sustain SoCal has focused on key sectors such as Energy, Water, Agriculture, Transportation, Hospitals and Healthcare, and Waste Stream Management. The organization aims to foster cooperation and collaboration among the public, private and academic sectors in the area of sustainability and cleantech within and around the greater Southern California region while serving as an information hub, a platform for advocacy, and providing mentorship and advisory with a view to further sustainable linkages. Sustain SoCal invites established and emerging cleantech companies, start-up companies, corporate organizations of all sizes, municipal/regional/state/national agencies, non-profit organizations, and investors to register for the event. Why Should You Attend? The Driving Mobility 9 event presents a unique opportunity to build a deep understanding of the evolving trends in mobility and advanced transportation. The event will host several industry stalwarts and sector experts, who will provide an insightful commentary on the state of the sector and future opportunities. Attendees will be able to learn from and interact directly with thought leaders across various sub-sectors in the mobility and transportation landscape. Furthermore, the event will provide a forum for exchanging ideas and exploring business opportunities and enable networking with large corporations, cleantech companies, local government, investors, academia, and non-profits. In addition, it will provide a platform to share best practices, a deeply educational experience for the broader community to engage with clean technology, and potential financial opportunities for investment professionals. How To Register? For more information on the event, visit here. To register, please submit the registration form at the earliest. For SoCal members, the event is free. So why wait?

• Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated
• The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd
• No additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus counts
• The reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking

The COVID-19 pandemic, from the start, has been characterized by the high unpredictability of the virus. Despite the best efforts of the scientific community to use the historical data and patterns of previous viruses, it is becoming apparent that the original presumptions are no longer valid. The original hypothesis was that once enough people created an immunity to COVID-19, it would stop the virus dead in its tracks; unfortunately, what they are learning is that herd immunity is unlikely to happen. Herd immunity occurs when a virus can’t spread because it keeps encountering people who have become immune to the specific virus. The idea is that a small group of people lacking resistance to the virus can be protected by the immune herd because it is less likely to spread to them. Even though the mentality that herd immunity can be successful through immunizations, scientists no longer believe that this is an appropriate management strategy for COVID-19 long-term. Two years after a COVID-19 vaccine was made available, fewer than 70% of Americans are fully vaccinated (https://ibn.fm/lcOKY). The pockets of unvaccinated people who lack any type of immunity to this ever-changing virus only provide the potential for the virus to grow and mutate as it spreads. Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). The score can be used to provide those tested with important answers to questions like:

• Are antibodies present?
• How are these antibodies present – vaccine or natural immune system response?
• Will this immunity status provide protection from the virus in the future?
• What is the best approach to creating immunity for that individual?

“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/pbmD3). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.” With the potential for herd immunity off the table, and federal COVID funds dwindling, supply rationing has begun. Of the current budget, the Biden Administration has reallocated $5 billion to purchase updated versions of the vaccine for fall. Since Congress has approved no new funding, the Administration is forced to use the remaining budget to consider the longer-term solutions, like fall when virus uptick increases. At this time, epidemiologists are concerned about the blind spots created due to the shift in focus from testing to more vaccine development. Without the increased testing efforts, it becomes impossible to track and isolate variants. Without the funding, further development on the COVID-19 front will be less likely to be sustainable. About Aditxt Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com. NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX